|Opportunity Name||TRANSCAN-3 Joint Transnational Call 2023: Translational Research on Cancer Epigenetics|
|Agency||Canadian Institutes for Health Research (CIHR)|
|Value||Up to $150,000/year|
|Duration||Up to 3 years|
|Pre-proposal due to FSc RO at email@example.com for full review||07-07-2023|
|Pre-proposal and fully signed ORS checklist due to FSc RO at firstname.lastname@example.org for mandatory review||07-14-2023|
|Pre-proposal and fully signed ORS checklist due at ORS for mandatory review||07-19-2023, by 9:00AM|
|Pre-proposal due at agency||07-21-2023, by 12:00PM CEST|
|Application due to FSc RO at email@example.com for full review||12-01-2023|
|Application and fully signed ORS checklist due to FSc RO at firstname.lastname@example.org for mandatory review||12-08-2023|
|Final application and fully signed ORS checklist due at ORS for mandatory review||12-13-2023, by 9:00AM|
|Application due at agency||12-15-2023, by 12:00PM CEST|
To improve the efficacy of current detection, diagnosis, prognosis and treatment of cancers through the development of novel approaches based on a better understanding of cancer epigenetics. In the context of translational research, this topic will comprise two general aims, each with several aims, which concur to the possible clinical applications. Proposals should cover one or several of the specific aims listed below and should be built from a sound hypothesis. Particular attention should be given to gender balance inclusion in order to intercept sex/gender differences and to consider the role of these differences in the addressed questions.
Aim 1) The role of epigenetics in cancer initiation and progression. These studies may aim to validate novel epigenetics-based biomarkers to improve detection, diagnosis, prognosis of cancers or response to therapies (using recently developed innovative approaches, multiomic approaches, single-cell analysis, patient-derived organoids, patient-derived xenografts, tumour samples collected from retrospective and/or prospective cohorts of patients or clinical trials).
- Specific aim 1.1: To understand cancer initiation and progression by characterisation of the epigenetic landscape.
- Specific aim 1.2: To define epigenetic features of cells in the tumour microenvironment that may promote tumour progression (e.g., immune cells, vascular cells, microbiota).
- Specific aim 1.3: To study the role of epigenetic modifications as predictors of cell persistence or treatment resistance.
- Specific aim 1.4: To validate epigenetic markers useful to improve early detection and diagnosis by exploring the correlation between epigenetics and clinical cancer manifestation.
Aim 2) Validation of new epigenetics-based therapeutic strategies to limit cancer progression, prevent relapse/recurrence or increase the efficiency or reduce toxicity of existing anti-cancer therapies.
- Specific aim 2.1: To validate novel therapeutic targets (novel targets should be evaluated in translational studies with regard to their impact on treatment efficacy, safety and patient reported outcomes).
- Specific aim 2.2: To study the potential use of epigenetic modulators to overcome resistance to anti-cancer therapies.
- Specific aim 2.3: To develop novel epidrugs/therapeutic approaches, through phase I and II clinical trials (investigating combinations of available treatments, new therapeutics, new administration schemes, etc.) to improve safety and efficacy of treatments (objective responses; patient reported outcomes regarding morbidity and quality of life; …).
- Specific aim 2.4: To develop novel theranostic approaches involving epigenetics of cancer. Approaches combining diagnostic (imaging technics) and targeted treatment to detect cancer cells and assess treatment efficacy (radionuclide, radiopharmaceuticals, nanoparticles, nanomaterial, …).
An essential pre-requisite for all proposals is the clinical relevance of the planned work.
TRANSCAN particularly welcome applications that propose novel interdisciplinary approaches from relevant fields of engineering, informatics, physics in addition to biology and medicine, provided that they are mindful of potential clinical need, patient and population impact.
Each research consortium must involve a minimum of three (3) and a maximum of six (6) eligible partners from at least three (3) different countries participating in the call. For further details on eligibility criteria, please visit the JTC 2023 webpage. Researchers in Canada are strongly encouraged to apply.
How to Apply
York University researchers are reminded that all applications for external research funding, including Letters of Intent, must be reviewed and approved by the Office of Research Services before they are submitted to the granting agency. For internal approval, the application must be accompanied by a completed ORS Checklist, which requires the Dean’s signature. Please send the complete application, with the finalized budget and a completed ORS checklist to email@example.com, five days prior to agency deadline.
ORS is accepting electronic applications – the process is outlined here.